title: Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.
authors: Gaelle
authors: G
authors: Serac
authors: Florence
authors: F
authors: Tubach
authors: Xavier
authors: X
authors: Mariette
authors: Dominique
authors: D
authors: Salmon-Céron
authors: Philippe
authors: P
authors: Ravaud
authors: Frederic
authors: F
authors: Lioté
authors: David
authors: D
authors: Laharie
authors: Jean-Marc
authors: JM
authors: Ziza
authors: Laurent
authors: L
authors: Marguerie
authors: Christine
authors: C
authors: Bonnet
authors: Geraldine
authors: G
authors: Falgarone
authors: Nathalie
authors: N
authors: Nicolas
authors: Olivier
authors: O
authors: Lortholary
authors: Olivier
authors: O
authors: Chosidow
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D016022:Case-Control Studies; D000068800:Etanercept; D005260:Female; D005602:France / Q000453:epidemiology; D006562:Herpes Zoster / Q000453:epidemiology* / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012306:Risk; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept